O-5 Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection

Document Details

Document Type
Pub Defense Publication
Publication Date
Jul 01, 2021
Source ID
10.1016/j.annonc.2021.05.009

Entities

People

  • A. Cercek
  • A. Zehir
  • Daniel R. Jones
  • Daniela Molena
  • E. Won
  • G. Jayakumaran
  • G. Ku
  • L. Diaz Jr.
  • M. Berger
  • M. Fox
  • M. Lumish
  • M. Segal
  • M. Weiser
  • N. Segal
  • S. Maron
  • S. Sabwa
  • T. Troso-sandoval
  • V. Strong
  • Y. Janjigian
  • Z. Stadler

Organizations

  • AstraZeneca
  • Basilea Pharmaceutica
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly and Company
  • Hoffmann-La Roche
  • Merck & Co.
  • National Cancer Institute
  • Pfizer
  • United States Department of Defense